Tech Company Financing Transactions
Avalanche Biotech Funding Round
Avalanche Biotech closed a $55 million Series B funding round on 4/23/2014. Investors included Venrock, Adage Capital Management and Deerfield Capital.
Transaction Overview
Company Name
Announced On
4/23/2014
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series B
Investors
Venrock (Lead Investor) (Bong Koh)
Proceeds Purpose
Proceeds from the Series B financing round will be used to advance the company's clinical programs in retinal disorders, including Avalanche's lead product, AVA-101, for wet AMD.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1035 O'Brien Dr. A
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Website
Email Address
Overview
Avalanche develops technologies and products for sustained delivery of therapeutic proteins to the eye to treat ophthalmologic disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Leone Patterson
Chief Medical Officer
Aaron Osborne
Chief Technical Officer
Thomas Leung
President
Mehdi Gasmi
VP - General Counsel
Jennifer Cheng
VP - Regulatory Affairs
Carla Fiankan
Browse more venture capital transactions:
Prev: 4/23/2014: HackSurfer venture capital transaction
Next: 4/23/2014: Kala Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs